2026-05-22T00:40:33Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/119102025-05-23T09:17:42Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Aye, Aye Mya Min author Bai, Xilian author Borrow, Ray author Bory, Sotharith author Carlos, Josefina author Caugant, Dominique A author Chiou, Chien-Shun author Dai, Vo Thi Trang author Dinleyici, Ener Cagri author Ghimire, Prakash author Handryastuti, Setyo author Heo, Jung Yeon author Jennison, Amy author Kamiya, Hajime author Tonnii Sia, Loong author Lucidarme, Jay author Marshall, Helen author Putri, Nina Dwi author Saha, Senjuti author Shao, Zhujun author Sim, James Heng Chiak author Smith, Vinny author Taha, Muhamed-Kheir author Van Thanh, Phan author Thisyakorn, Usa author Tshering, Kinley author Vazquez-Moreno, Julio Alberto author Veeraraghavan, Balaji author Yezli, Saber author Zhu, Bingqing author 2020-11 The degree of surveillance data and control strategies for invasive meningococcal disease (IMD) varies across the Asia-Pacific region. IMD cases are often reported throughout the region, but the disease is not notifiable in some countries, including Myanmar, Bangladesh and Malaysia. Although there remains a paucity of data from many countries, specific nations have introduced additional surveillance measures. The incidence of IMD is low and similar across the represented countries (<0.2 cases per 100,000 persons per year), with the predominant serogroups of Neisseria meningitidis being B, W and Y, although serogroups A and X are present in some areas. Resistance to ciprofloxacin is also of concern, with the close monitoring of antibiotic-resistant clonal complexes (e.g., cc4821) being a priority. Meningococcal vaccination is only included in a few National Immunization Programs, but is recommended for high-risk groups, including travellers (such as pilgrims) and people with complement deficiencies or human immunodeficiency virus (HIV). Both polysaccharide and conjugate vaccines form part of recommendations. However, cost and misconceptions remain limiting factors in vaccine uptake, despite conjugate vaccines preventing the acquisition of carriage. J Infect. 2020 Nov;81(5):698-711. 10.1016/j.jinf.2020.07.025 1532-2742 The Journal of infection 32730999 http://hdl.handle.net/20.500.12105/11910 Antibiotic resistance Asia-Pacific Carriage Conjugate vaccine Emerging strains High-risk groups Immunization program Meningococcal disease Neisseria meningitidis Polysaccharide vaccine Refugees Serogroup Surveillance Vaccination Bacterial meningitis Meningococcal disease surveillance in the Asia-Pacific region (2020): The global meningococcal initiative